Document ID: chunk:federal_register_of_legislation:F2020L00500:reg:9
Version: federal_register_of_legislation:F2020L00500
Segment Type: reg
Provision Reference: reg 9
Character Range: 3954–5743

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting polyarteritis nodosa or death from polyarteritis nodosa with the circumstances of a person's relevant service:
(1)          having infection with hepatitis B virus at the time of the clinical onset of polyarteritis nodosa;
(2)          having infection with hepatitis C virus at the time of the clinical onset of polyarteritis nodosa;
(3)          having infection with human immunodeficiency virus at the time of the clinical onset of polyarteritis nodosa;
(4)          being treated with minocycline for at least the 12 months before the clinical onset of polyarteritis nodosa;
            Note: Antineutrophil cytoplasmic antibodies may be associated with minocycline-induced polyarteritis nodosa.
(5)          having hairy cell leukaemia before the clinical onset of polyarteritis nodosa;
(6)          having had a hepatitis B vaccination within the three months before the clinical onset of polyarteritis nodosa;
(7)          having infection with hepatitis B virus at the time of the clinical worsening of polyarteritis nodosa;
(8)          having infection with hepatitis C virus at the time of the clinical worsening of polyarteritis nodosa;
(9)          having infection with human immunodeficiency virus at the time of the clinical worsening of polyarteritis nodosa;
(10)      being treated with minocycline for at least the 12 months before the clinical worsening of polyarteritis nodosa;
            Note: Antineutrophil cytoplasmic antibodies may be associated with minocycline-induced polyarteritis nodosa.
(11)      inability to obtain appropriate clinical management for polyarteritis nodosa.